ES3026437T3 - Il1ra derived peptides for treatment of diabetic nephropathy - Google Patents

Il1ra derived peptides for treatment of diabetic nephropathy Download PDF

Info

Publication number
ES3026437T3
ES3026437T3 ES21742823T ES21742823T ES3026437T3 ES 3026437 T3 ES3026437 T3 ES 3026437T3 ES 21742823 T ES21742823 T ES 21742823T ES 21742823 T ES21742823 T ES 21742823T ES 3026437 T3 ES3026437 T3 ES 3026437T3
Authority
ES
Spain
Prior art keywords
compound
seq
amino acid
peptides
diabetic nephropathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21742823T
Other languages
English (en)
Spanish (es)
Inventor
Eva Steiness
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serodus ApS
Original Assignee
Serodus ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serodus ApS filed Critical Serodus ApS
Application granted granted Critical
Publication of ES3026437T3 publication Critical patent/ES3026437T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES21742823T 2021-07-13 2021-07-13 Il1ra derived peptides for treatment of diabetic nephropathy Active ES3026437T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2021/069450 WO2023284947A1 (en) 2021-07-13 2021-07-13 Il1ra derived peptides for treatment of diabetic nephropathy

Publications (1)

Publication Number Publication Date
ES3026437T3 true ES3026437T3 (en) 2025-06-11

Family

ID=76958978

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21742823T Active ES3026437T3 (en) 2021-07-13 2021-07-13 Il1ra derived peptides for treatment of diabetic nephropathy

Country Status (8)

Country Link
US (1) US20240216464A1 (https=)
EP (1) EP4351617B1 (https=)
JP (1) JP7839260B2 (https=)
CN (1) CN117642174A (https=)
AU (1) AU2021455992A1 (https=)
CA (1) CA3226176A1 (https=)
ES (1) ES3026437T3 (https=)
WO (1) WO2023284947A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
KR101317045B1 (ko) * 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
ES2600616T3 (es) * 2011-03-14 2017-02-10 Phlogo Aps Antagonistas del receptor de la interleucina-1
WO2017063657A1 (en) * 2015-10-14 2017-04-20 Phlogo Aps Il1ra-derived peptide antagonist
WO2018022982A1 (en) * 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development

Also Published As

Publication number Publication date
AU2021455992A1 (en) 2024-01-18
CA3226176A1 (en) 2023-01-19
JP7839260B2 (ja) 2026-04-01
EP4351617B1 (en) 2025-03-26
WO2023284947A1 (en) 2023-01-19
EP4351617C0 (en) 2025-03-26
JP2024525669A (ja) 2024-07-12
EP4351617A1 (en) 2024-04-17
US20240216464A1 (en) 2024-07-04
CN117642174A (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
Takashima et al. Stromal cell–derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy
Bidwell III et al. A kidney-selective biopolymer for targeted drug delivery
ES2901477T3 (es) Nuevos análogos de urocortina-2 modificados con ácidos grasos para el tratamiento de la diabetes y la enfermedad renal crónica
JP2021185178A (ja) 胆汁酸に関係した障害の治療方法
CN102389413B (zh) 用于治疗糖尿病的组合物及其应用
CN105705160B (zh) Il-22二聚体在制备用于治疗胰腺炎的药物中的用途
Zhang et al. Mitigation effect of an FGF-2 peptide on acute gastrointestinal syndrome after high-dose ionizing radiation
JP5197012B2 (ja) 大腸連続性を伴う短腸症候群患者の治療
CN116323649A (zh) 膜联蛋白a1 n-末端肽的制剂和方法
Pasi et al. Novel multimeric IL-1 receptor antagonist for the treatment of rheumatoid arthritis
ES3026437T3 (en) Il1ra derived peptides for treatment of diabetic nephropathy
KR20150048663A (ko) 패혈증 치료를 위한 티모신 알파의 용도
Li et al. The complement-targeted inhibitor mini-FH protects against experimental periodontitis via both C3-dependent and C3-independent mechanisms
CN118420740A (zh) 一类半抗原和脂肪酸双修饰的BimBH3模拟肽及其制备方法和应用
ES3054546T3 (en) Il-4 derived peptide fragments for use in the treatment of diabetic nephropathy
CA3244198C (en) Il-4 derived peptide fragments for use in the treatment of diabetic nephropathy
US12582695B2 (en) Compositions and methods for treating glioma
Yang et al. Macrophages promote heat stress nephropathy in mice via the C3a-C3aR-TNF pathway
CN105936646A (zh) 迷你蛋白及其应用
WO2024011946A1 (en) Polypeptide dimers for the treatment of systemic sclerosis
WO2017063657A1 (en) Il1ra-derived peptide antagonist
EP3389696B1 (en) Ameliorating systemic sclerosis with death receptor agonists
CN116139247A (zh) 一类订书肽化合物在制备治疗肺纤维化的药物中的应用
Ramwell Estradiol and Accelerated Transplant Arteriosclerosis
Bonnet Tumor necrosis factor inhibitors as novel therapeutic tools for vascular remodeling diseases 2